This session covers the experiences of the radiopharmaceutical therapy programs at three institutions.

This session covers the history of elective nodal irradiation and how doses were originally selected. Also covered will be how these doses changed as the field moved to IMRT. Failure rates in the elective nodal fields is examined.

There are many ongoing advances in neoadjuvant immunotherapy in curative-intent head and neck cancer, yet optimal incorporation and biomarkers remain undefined.

This session explores critical operational, clinical and administrative considerations for maturing and optimizing established radiopharmaceutical and theranostics programs.

Virally mediated head and neck cancers caused by the Human Papilloma Virus (HPV) and the Epstein-Barr Virus (EBV) are increasing in the United States and are a global health problem.

Advanced cutaneous SCC is becoming more prevalent, with more aggressive disease noted.

This session reviews the latest science in the field of radiopharmaceutical therapy.

This session reviews head and neck cancers from a patient perspective.

This session reviews head and neck cancers from a patient perspective.

Increasing access and addressing unmet needs are critical to the continued growth and adoption of radiopharmaceutical therapy. This session summarizes the current barriers to access and discuss solutions to increase physician and patient access to these important therapies.